EGFR and non-small cell lung carcinoma: Focusing on the most relevant of these mutations, we and others have reported outcomes in erlotinib- or gefitinib-treated NSCLC cases carrying at baseline the exon 18 G719X (G719C, G719S, G719A or G719D), exon 20 S768I, or exon 21 L861Q EGFR-mutations, which are present in 1–8% of EGFRM+ NSCLCs and often occur simultaneously as complex mutants (G719X+S768I/L861Q) [1,51,75,76,77,78,79,80].